CASP1 and acute coronary syndrome: In studies of acute coronary syndrome (ACS), colchicine has been shown to prevent NLPR3 inflammasome-induced caspase-1 activation, leading to decreased levels of interleukin IL-1b, IL-18, and IL-6 and CRP and a reduction in mortality from major cardiovascular events [13–15].